PIROXICAM IN THE TREATMENT OF PRIMARY DYSMENORRHEA
L. Wilhelmsson, K. Jönsson, L. Hailing, Martin Hermann, J. Jäderling, C. Lindell, Björn Nilsson, F. Sannum, Anders Haglund
Abstract
L. Wilhelmsson, K. Jönsson, L. Hailing, Martin Hermann, J. Jäderling, C. Lindell, Björn Nilsson, F. Sannum, Anders Haglund
Abstract
In double-blind, crossover studies, piroxicam was compared with naproxen sodium and with placebo. The different parameters studied were pain intensity, patient's opinion of the drugs tested, complementary pharmacological treatment, ability to work, overall effect, treatment preference, and side effects. It was concluded that piroxicam was comparable to naproxen sodium and that piroxicam was significantly better than placebo, as regards these parameters. It was also concluded that piroxicam has an effect equivalent to that of naproxen sodium, an accepted treatment for dysmenorrhea.
OpenAlex reports 11 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
In double-blind, crossover studies, piroxicam was compared with naproxen sodium and with placebo. The different parameters studied were pain intensity, patient's opinion of the drugs tested, complementary pharmacological treatment, ability to work, overall effect, treatment preference, and side effects. It was concluded that piroxicam was comparable to naproxen sodium and that piroxicam was significantly better than placebo, as regards these parameters. It was also concluded that piroxicam has an effect equivalent to that of naproxen sodium, an accepted treatment for dysmenorrhea.
Key concepts: Piroxicam, Medicine, Naproxen Sodium, Naproxen, Placebo, Crossover study, Double blind, Internal medicine